Jupiter Asset Management Ltd. Has $518,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Jupiter Asset Management Ltd. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 92.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,077 shares of the biopharmaceutical company’s stock after selling 90,520 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Gilead Sciences were worth $518,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Capital World Investors grew its position in Gilead Sciences by 2.0% during the fourth quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock valued at $6,753,350,000 after purchasing an additional 1,642,736 shares in the last quarter. Capital Research Global Investors grew its position in Gilead Sciences by 3.0% during the fourth quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock valued at $4,832,824,000 after purchasing an additional 1,743,418 shares in the last quarter. Wellington Management Group LLP grew its position in Gilead Sciences by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after acquiring an additional 2,350,550 shares in the last quarter. Norges Bank bought a new stake in Gilead Sciences in the fourth quarter worth approximately $1,301,624,000. Finally, Parnassus Investments LLC grew its position in Gilead Sciences by 0.3% in the fourth quarter. Parnassus Investments LLC now owns 11,952,057 shares of the biopharmaceutical company’s stock worth $968,236,000 after acquiring an additional 36,686 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD traded down $0.95 during trading hours on Friday, hitting $72.56. The stock had a trading volume of 5,571,805 shares, compared to its average volume of 7,521,859. The company’s fifty day moving average is $67.13 and its two-hundred day moving average is $71.43. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The stock has a market capitalization of $90.40 billion, a price-to-earnings ratio of 201.56, a P/E/G ratio of 3.11 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.37 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 3.71 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.24%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s payout ratio is presently 855.56%.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent research reports. Barclays decreased their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Maxim Group decreased their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. UBS Group decreased their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $74.00 price objective on shares of Gilead Sciences in a report on Monday, July 1st. Twelve investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Hold” and an average price target of $83.35.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.